GLP-1 Studies Suggest Benefits Extend to Infectious Diseases
(MedPage Today) -- Recent studies suggest that people with type 2 diabetes on GLP-1 receptor agonists were less likely to develop tuberculosis (TB) or be hospitalized or die from infections. In an international study of more than 7 million people...
Two recent studies on GLP-1 receptor agonists suggest these diabetes medications may offer broader benefits than previously thought. In an international analysis of over 7 million individuals, GLP-1 drugs were linked with lower risk of tuberculosis (TB) compared to other diabetes medications, including DPP-4 inhibitors, sulfonylureas, metformin, and SGLT2 inhibitors.
The findings, published in Nature Communications, indicate GLP-1 therapies may provide additional protection against infection beyond their established metabolic advantages.
Building on the anti-infection insights, a U.S. real-world study of more than 50,000 adults with type 2 diabetes and atherosclerotic cardiovascular disease found tirzepatide, a GLP-1 drug, was associated with significantly lower 1-year risks for serious infections compared to the DPP-4 inhibitor sitagliptin. Published in The BMJ, the research from Harvard Medical School in Boston showed tirzepatide users had reduced mortality, hospitalization, and urinary tract infection risks related to infections, as well as lower all-cause mortality.
The study's authors suggest the survival benefit may stem from tirzepatide's ability to reduce serious bacterial infections.
Together, the studies support a recent review finding GLP-1 medications have protective associations against infection-related outcomes, particularly serious infections. Diabetes raises the risk for active TB, and obesity is linked to 1 in 10 infection-related deaths in adults. Past research has hinted that obesity may increase infection risk through factors like systemic inflammation and metabolic disturbances.
GLP-1 drugs, according to the studies' authors, may influence infection susceptibility and outperform other diabetes medications in lowering infection risk.
In preclinical studies, GLP-1 receptor agonists have shown promise in enhancing infection defense in mice. By restoring host defense against infection through improved neutrophil function, GLP-1 drugs may provide superior anti-infective effects compared to conventional diabetes treatments. This benefit may stem from GLP-1 medications' impact on immune cell function, independent of their established role in glycemic control.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
